ConductScience.org, home

Paper41002563

Tumor Immune Microenvironment and Current Status of Immune Checkpoint Inhibitor Therapy in Colorectal Cancer Liver Metastasis.

Cao D and 1 other. Curr Oncol, 2025. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. Tumor Immune Microenvironment and Current Status of Immune Checkpoint Inhibitor Therapy in Colorectal Cancer Liver Metastasis. Papers, record 41002563. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41002563

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Tumor Immune Microenvironment and Current Status of Immune Checkpoint Inhibitor Therapy in Colorectal Cancer Liver Metastasis.
PubMed
Journal
Curr Oncol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
2.09, provisional
iCite
Revised in PubMed
2025-09-28
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cao DDandan
2Zhou AAiping

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Colorectal NeoplasmsMajor topic
Immune Checkpoint InhibitorsMajor topic
Liver NeoplasmsMajor topic
Tumor MicroenvironmentMajor topic
Humans

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
2023ZD0501600Noncommunicable Chronic Diseases-National Science and Technology Major ProjectPubMed

Source PubMed

Download CSV of grants

References60

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136892833Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial.JAMA Oncol2023https://conductscience.org/library/papers/36892833PubMed
231590148Comparison of Mismatch Repair Status Between Primary and Matched Metastatic Sites in Patients With Colorectal Cancer.J Natl Compr Canc Netw2019https://conductscience.org/library/papers/31590148PubMed
323177514Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet2013https://conductscience.org/library/papers/23177514PubMed
435705369Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases.Gut2023https://conductscience.org/library/papers/35705369PubMed
538865678
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study.
J Clin Oncol2024https://conductscience.org/library/papers/38865678PubMed
638833658Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.J Clin Oncol2024https://conductscience.org/library/papers/38833658PubMed
718421054Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.J Clin Oncol2008https://conductscience.org/library/papers/18421054PubMed
835246503Colorectal liver metastasis: molecular mechanism and interventional therapy.Signal Transduct Target Ther2022https://conductscience.org/library/papers/35246503PubMed
937480104Liver metastasis from colorectal cancer: pathogenetic development, immune landscape of the tumour microenvironment and therapeutic approaches.J Exp Clin Cancer Res2023https://conductscience.org/library/papers/37480104PubMed
1035427471
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.
Lancet Oncol2022https://conductscience.org/library/papers/35427471PubMed
1135636444
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol2022https://conductscience.org/library/papers/35636444PubMed
1238024475Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215).EClinicalMedicine2023https://conductscience.org/library/papers/38024475PubMed
1332849517Myeloid-Derived Suppressor Cells in Colorectal Cancer.Front Immunol2020https://conductscience.org/library/papers/32849517PubMed
1424120480Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.Lancet Oncol2013https://conductscience.org/library/papers/24120480PubMed
1538572751Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024https://conductscience.org/library/papers/38572751PubMed
1628192899Comparison of the Mismatch Repair System between Primary and Metastatic Colorectal Cancers Using Immunohistochemistry.J Pathol Transl Med2017https://conductscience.org/library/papers/28192899PubMed
1732379280Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.JAMA Oncol2020https://conductscience.org/library/papers/32379280PubMed
1829754777International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.Lancet2018https://conductscience.org/library/papers/29754777PubMed
1936707233Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade.Gut2023https://conductscience.org/library/papers/36707233PubMed
2034725151Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy.Proc Natl Acad Sci U S A2021https://conductscience.org/library/papers/34725151PubMed

See all 60 referencesDownload CSV of references

Cited by10

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
42983433Efficacy and safety of regorafenib plus PD-1/PD-L1 inhibitors for metastatic colorectal cancer: a systematic review and meta-analysis.World J Surg Oncol2026https://conductscience.org/library/papers/42983433PubMed
42980805Mast cell-derived SPP1 promotes colorectal cancer liver metastasis by suppressing BTG1-mediated JUN degradation.Cell Mol Life Sci2026https://conductscience.org/library/papers/42980805PubMed
42723950Longitudinal analysis of genomic and immune differences between primary and metastatic nasopharyngeal carcinoma for precision oncology.Front Oncol2026https://conductscience.org/library/papers/42723950PubMed
42640498Noninvasive molecular imaging signatures of histopathological growth patterns in colorectal cancer liver metastases.Clin Exp Metastasis2026https://conductscience.org/library/papers/42640498PubMed
42558893Targeting molecular residual disease and immune escape in colorectal cancer recurrence: biomarker-guided immunotherapy and cell therapies.Front Med (Lausanne)2026https://conductscience.org/library/papers/42558893PubMed
42358994Colorectal cancer liver metastasis: immunosuppressive microenvironment, signaling pathways, and emerging therapeutic strategies.Front Immunol2026https://conductscience.org/library/papers/42358994PubMed
42253947Organ-specific pre-metastatic and metastatic niches in colorectal cancer: "discrepancy in response to immune checkpoint inhibitors in liver and lung metastasis".Front Immunol2026https://conductscience.org/library/papers/42253947PubMed
41832460The prognostic value of immunoscore in colorectal cancer liver metastases: a meta-analysis reveals the superiority of metastatic over primary tumor profiling.BMC Cancer2026https://conductscience.org/library/papers/41832460PubMed
41749820Disparities in Tumor Microenvironment Between Primary and Metastatic Colorectal Cancer: Impact on Immune Infiltration and Survival.Cancers (Basel)2026https://conductscience.org/library/papers/41749820PubMed
41228231Genetic, Epidemiological, Clinical, and Therapeutic Trajectories in Colon and Rectal Cancers.Cancers (Basel)2025https://conductscience.org/library/papers/41228231PubMed

Download CSV of cited by

Genes39

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CCL186362PubTator's text mininghttps://conductscience.org/library/genes/6362NCBI Gene
CD1639332PubTator's text mininghttps://conductscience.org/library/genes/9332NCBI Gene
CD27939PubTator's text mininghttps://conductscience.org/library/genes/939NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD33945PubTator's text mininghttps://conductscience.org/library/genes/945NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD44960PubTator's text mininghttps://conductscience.org/library/genes/960NCBI Gene
CD68968PubTator's text mininghttps://conductscience.org/library/genes/968NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CGAS115004PubTator's text mininghttps://conductscience.org/library/genes/115004NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
CXCL83576PubTator's text mininghttps://conductscience.org/library/genes/3576NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
GPX42879PubTator's text mininghttps://conductscience.org/library/genes/2879NCBI Gene
HDAC99734PubTator's text mininghttps://conductscience.org/library/genes/9734NCBI Gene
ICOS29851PubTator's text mininghttps://conductscience.org/library/genes/29851NCBI Gene
IFNG3458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
IL103586PubTator's text mininghttps://conductscience.org/library/genes/3586NCBI Gene
IL183606PubTator's text mininghttps://conductscience.org/library/genes/3606NCBI Gene
IL1B3553PubTator's text mininghttps://conductscience.org/library/genes/3553NCBI Gene

See all 39 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41002563

GET https://conductscience.org/api/papers/v1/41002563/references?page=2